Chronic Lymphocytic Leukemia

Lydia Scarfò, MD, discusses future research directions for BGB-16673 in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

Cyrus M. Khan, MD, discusses the role of second-generation BTK inhibitors and their implications for clinical practice in the CLL treatment paradigm.

Tahla Munir, MBChB, PhD, discusses the rationale for a MAIC of the phase 3 SEQUOIA and AMPLIFY trials in chronic lymphocytic leukemia.

The NMPA has approved lisaftoclax in adult patients with relapsed/refractory CLL/SLL.

Lydia Scarfò, MD, details the early efficacy and safety profile of BTK degrader BGB-16673 for the treatment of patients with relapsed/refractory CLL/SLL.

Fixed-duration ibrutinib plus venetoclax was effective with nearly 70 months of follow-up in patients with untreated CLL/SLL.

Lydia Scarfò, MD, explains the rationale for evaluating the BTK degrader BGB-16673 for patients with relapsed/refractory CLL.

The FDA has eliminated REMS programs for BCMA- and CD19-directed autologous CAR T-cell therapies approved for multiple myeloma and select types of lymphoma/leukemia.

The FDA updated the labels for liso-cel and ide-cel to reduce monitoring select requirements and remove REMS programs for the CAR T-cell therapies.

Alexey Danilov, MD, PhD, shares key developments and areas of debate from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.

Talha Munir, MBChB, PhD, discusses findings from an Indirect comparative of zanubrutinib vs acalabrutinib plus venetoclax in treatment-naive CLL.

The top 5 OncLive videos of the week cover insights in CLL, multiple myeloma, follicular lymphoma, and extrapulmonary neuroendocrine carcinomas.

Tafasitamab combination gets approval in follicular lymphoma, FDA declines to expand label for talazoparib plus enzalutamide in mCRPC, and more.

Paolo Ghia, MD, PhD, discusses the efficacy of fixed-duration ibrutinib plus venetoclax in patients with CLL/SLL.

Venetoclax plus rituximab displayed OS and PFS benefits vs BR after long-term follow-up in relapsed/refractory CLL.

Mazyar Shadman, MD, MPH, discusses key efficacy and safety findings from arm D of the SEQUOIA trial of first-line zanubrutinib plus venetoclax in CLL/SLL.

Hematologic oncology experts share the studies they were most excited to see presented at the 2025 EHA Congress.

PROs were improved with pirtobrutinib among evaluable patient with CLL/SLL treated during the BRUIN CLL-321 trial.

A matching-adjusted indirect comparison of zanubrutinib and acalabrutinib/venetoclax showed favorability towards zanubrutinib in patients with CLL.

BGB-16673 showed a favorable safety profile and promising antitumor activity in relapsed/refractory CLL/SLL, with responses seen across baseline mutations.

The FDA has approved a tablet formulation of zanubrutinib for use in all 5 approved indications of the capsule formulation.

Time-limited therapy with acalabrutinib plus venetoclax with or without obinutuzumab is approved in the European Union for untreated patients with CLL.

Zanubrutinib in combination with venetoclax was highly active in patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.

Zanubrutinib retained long-term efficacy as a frontline treatment in CLL/SLL harboring 17p deletions.

Zanubrutinib showed high response rates and durable responses among Japanese patients with CLL/SLL and Waldenström macroglobulinemia.